Indivior Completes Cancellation of London Stock Exchange Listing
Indivior PLC has officially completed the cancellation of its secondary listing on the London Stock Exchange, effective from 08:00 a.m. UK time on July 25, 2025. The decision follows an announcement made on June 2, 2025, and allows the company to concentrate on its primary listing on the Nasdaq Stock Market.
This move means that Indivior’s Ordinary Shares will no longer be part of the Equity Shares (Transition) category of the Official List maintained by the UK Financial Conduct Authority. The company has made available an FAQ document for shareholders regarding the implications of the London Delisting, which can be accessed on its official website.
Indivior’s Focus on Opioid Use Disorder Treatments
Indivior is a global pharmaceutical company that aims to address the challenges associated with opioid use disorder (OUD). With a commitment to transforming OUD into a recognized chronic disease, Indivior strives to ensure that patients around the world have access to effective, evidence-based treatments.
Headquartered in Richmond, Virginia, Indivior employs over 1,000 individuals and offers its portfolio of OUD treatments in more than 30 countries. The company is actively developing a pipeline of product candidates designed to enhance its existing offerings in this critical area.
For further information about Indivior and its initiatives, visit the company’s website or connect with them on LinkedIn. The company emphasizes its dedication to making a real difference in the lives of those affected by opioid use disorder.
